Reports Q1 revenue $532,000, consensus $420,000. “With results imminent for our ENLIGHTEN 1 pivotal Phase 3 study of LYR-210 in CRS, we are laser-focused on delivering the topline data in May,” said Maria Palasis, Ph.D., President and CEO of Lyra Therapeutics. “We believe that LYR-210 has the potential to revolutionize the treatment of CRS by delivering a six-month therapy designed to provide long-acting relief that addresses the widespread need to overcome current treatment limitations faced by millions of patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYRA:
- Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Lyra Therapeutics Announces Board and Committee Changes
- Lyra Therapeutics management to meet with Cantor Fitzgerald
- Lyra Therapeutics price target lowered to $11 from $12 at BofA